EP0966438A1 - Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices - Google Patents
Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matricesInfo
- Publication number
- EP0966438A1 EP0966438A1 EP98900334A EP98900334A EP0966438A1 EP 0966438 A1 EP0966438 A1 EP 0966438A1 EP 98900334 A EP98900334 A EP 98900334A EP 98900334 A EP98900334 A EP 98900334A EP 0966438 A1 EP0966438 A1 EP 0966438A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- aryl
- alkoxy
- aryloxy
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to arylsulfonylamino hydroxamic acid derivatives which are inhibitors of matrix metalloproteinases or the production of tumor necrosis factor (TNF) and as such are useful in the treatment of a condition selected from the group consisting of arthritis,
- the compounds of the present invention may be used in combination therapy with standard non- steroidal anti-inflammatory drugs (hereinafter NSAID'S) and analgesics for the treatment of
- cytotoxic drugs such as ad ⁇ amycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and alkaloids, such as vinc ⁇ stine, in the treatment of cancer
- This invention also relates to a method of using such compounds in the treatment of the above diseases in mammals, especially humans, and to pharmaceutical compositions useful therefor 20
- Matrix-degrading metalloproteinases such as gelatmase, stromelysin and collagenase, are involved in tissue matrix degradation (e g collagen collapse) and have been implicated in many pathological conditions involving abnormal connective tissue and basement membrane matrix metabolism, such as arthritis (e . 25 osteoarth ⁇ tis and rheumatoid arthritis), tissue uiceration (e g .
- Tumor necrosis factor is recognized to be involved in many infectious and auto-immune 30 diseases (W Fiers, FEBS Letters. 1991, 285, 199) Furthermore, it has been shown that TNF is the prime mediator of the inflammatory response seen in sepsis and septic shock (C E Spooner et al , Clinical Immunology and Immunopatholo ⁇ v. 1992, 62 S11) Summarv of the Invention
- the present invention relates to a compound of the formula
- R 2 is hydrogen or (C r C 6 )alkyl
- R 3 and R 4 are independently selected from the group consisting of hydrogen, (C 1 -C ⁇ )alkyl, trifluoromethyl, tnfluoromethyl(C r C 6 )alkyl, (C r C 6 )alkyl(d ⁇ fluoromethylene), (C 1 -C 3 )alkyl(d ⁇ fluoromethylene)(C 1 -C 3 )alkyl, (C 6 -C 10 )aryl, (C 2 -C 9 )heteroaryl,
- any of the carbon atoms of said ring, capable of forming an additional bond may be optionally substituted by a substituent (preferably zero to three substituents) independently selected from the group consisting of fluoro, chloro, bromo, (C 1 -C 6 )alkyl, (C r C 6 )alkoxy, perfluoro(C r C 3 )alkyl, perfluoro(C 1 -C 3 )alkoxy and (C 6 -C 10 )aryloxy, R is R O or R R N wherein R 6 and R 7 are each independently selected from the group consisting of hydrogen, (C C 6 )alkyl, (C 6 -C 10 )aryl(C C 6 )alkyl or (C 2 -C 9 )heteroaryl(C r C 6 )alkyl, wherein each of said (C 6 -C 10 )aryl and (C 2 -C 9 )heteroaryl moieties of said (C 6 -
- R 8 is piperazinyl, (C 1 -C 6 )alkylp ⁇ peraz ⁇ nyl, (C 6 -C 10 )arylp ⁇ peraz ⁇ nyl,
- Q is (C r C 6 )alkyl, (C 6 -C 10 )aryl, (C 6 -C 10 )aryloxy(C 6 -C 10 )aryl, (C 6 -C 10 )aryl(C 6 -C 10 )aryl, (C 6 - C 10 )aryl(C 6 -C 10 )aryl(C 1 -C 6 )alkyl, (C 6 -C 10 )aryloxy(C 2 -C 9 )heteroaryl, (C 2 -C 9 )heteroaryl, (C 2 - C 9 )heteroaryl(C 2 -C 9 )heteroaryl, (C 1 -C 6 )alkyl(C 6 -C 10 )aryl, (C 1 -C 6 )alkoxy(C 6 -C 10 )aryl, (C 6 - C 10 )aryl(C r C 6 )alkoxy(C 6 -
- the present invention also relates to the pharmaceutically acceptable acid addition salts of compounds of the formula I
- the acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, ]_ ⁇ _, salts containing pharmacologically acceptable anions, such as the hydrochlonde, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate []_e_, 1 ,1'-methylene-b ⁇ s-(2-hydroxy-3- naphthoate)]saltsaltsaltsalt
- the invention also relates to base addition salts of formula I
- the chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula I that are acidic in nature are those that form non-toxic base salts with such compounds
- Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e g . potassium and sodium) and alkaline earth metal cations (e g .
- ammonium or water- soluble amine addition salts such as N-methylglucam ⁇ ne-(meglum ⁇ ne), t ⁇ methyl-ammonium or diethylammonium, and the lower alkanolammonium salts such t ⁇ s-(hydroxymethyl)- methylammonium and other base salts of pharmaceutically acceptable organic amines
- alkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof
- alkoxy includes O-alkyl groups wherein “alkyl” is defined above
- aryl as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl
- heteroaryl includes an organic radical derived from an aromatic heterocyclic compound by removal of one hydrogen, such as pyridyl, furyl, pyroyi, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, pyrazinyl, py ⁇ midyl, quinolyl, isoquinoly., benzofuryl, isobenzofuryl, benzothienyl, pyrazolyl, indolyl, isoindolyl, punnyl, carbazolyl, isoxazolyl, thiazolyl, oxazolyl, benzthiazolyl or benzoxazolyl
- acyl as used herein, unless otherwise indicated, includes a radical of the general formula RCO wherein R is alkyl, alkoxy, aryl, arylalkyl or arylalkoxy
- acyloxy includes O-acyl groups wherein "acyl” is defined above
- the compound of formula I may have chiral centers and therefore exist in different diaste ⁇ ome ⁇ c or enantiome ⁇ c forms
- This invention relates to all optical isomers and stereoisomers of the compounds of formula I and mixtures thereof
- Preferred compounds of formula I include those wherein R 1 is OH and R 2 is hydrogen
- Other preferred compounds of formula I include those wherein both R 3 and R 4 are (C r C 6 )alkyl or R 3 and R 4 are taken together to form an optionally substituted (C 3 -C 6 )cycloalkyl ring or a benzo-fused(C 3 -C 6 )cycloalkyl ring or a group of the formula
- Other preferred compounds of formula I include those wherein R 1 is hydroxy
- Other preferred compounds of formula I include those wherein Q is (C 6 -C 10 )aryl or (C ⁇ - C 10 )aryloxy(C 6 -C 10 )aryl, wherein each (C 6 -C 10 )aryl moieties of said is (C 6 -C 10 )aryl or (C 6 - C 10 )aryloxy(C 6 -C 10 )aryl groups may be optionally substituted with one or more substituents independently selected from fluoro, chloro, bromo, (C r C ⁇ )alkyl, (C r C 6 )alkoxy or perfluoro(C 1 - C 3 )alkyl
- More preferred compounds of formula I include those wherein Q is phenyl or phenoxyphenyl optionally substituted with one or more substituents independently selected from fluoro, chloro, bromo, (C r C 6 )alkyl, (C r C 6 )alkoxy or perfluoro(C 1 -C 3 )alkyl, more preferably the substituents are selected from fluoro, chloro, (C r C 6 )alkoxy or (C r C 6 )alkyl, most preferably the substituent is in the 4-pos ⁇ t ⁇ on
- Specific preferred compounds of formula I include the following (2S)-2,N-d ⁇ hydroxy-3-(4-methoxybenzenesulfonyl)prop ⁇ onam ⁇ de, 3-[4-(4-fluorophenoxy)phenylsulfonyl]-2,N-d ⁇ hydroxyprop ⁇ onam ⁇ de, 2,N-d ⁇ hydroxy-2-[1-(4-methoxybenzenesulfonyl)cyclobutyl]acetam ⁇ de
- the present invention also relates to a pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, osteoporosis, cancer, synergy with cytotoxic anticancer agents, tissue uiceration, macular degeneration, restenosis, pe ⁇ odontal disease, epidermolysis bullosa, sclentis, in combination with standard NSAID'S and analgesics and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of
- the present invention also relates to a method for treating a condition selected from the group consisting of arthritis, osteoporosis, cancer, tissue uiceration, macular degeneration, restenosis, pe ⁇ odontal disease, epidermolysis bullosa, sclentis, compounds of formula I may be used in combination with standard NSAID'S and analgesics and in combination with cytotoxic anticancer agents, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an amount of a compound of formula I or a pharmaceutically acceptable salt thereof effective in treating such a condition
- TNF tumor necrosis factor
- Scheme 1 refers to the preparation of compounds of the formula I, wherein R 3 and R 4 are hydrogen
- a compound of the formula i is prepared from a compound of the formula II by hydrogenolysis under an atmosphere of hydrogen in the presence of a catalyst in a reaction inert solvent
- Suitable catalysts include 5% palladium on barium sulfate or 5% palladium on carbon, preferably 5% palladium on barium sulfate
- Suitable solvents include an alcohol such as ethanol, methanol or isopropanol, preferably methanol
- the aforesaid reaction may be performed at a pressure from about 1 to about 5 atmospheres, preferably about 3 atmospheres
- Suitable temperatures for the aforesaid reaction range from about 20°C (room temperature) to about 60°C, preferably the temperature may range from about 20°C to about 25°C (i e room temperature)
- the reaction is complete within about 0 5 hours to about 5 hours, preferably about 3 hours
- the compound of formula II is prepared from a compound of formula III by reaction with O-benzylhydroxylamine hydrochlo ⁇ de, an activating agent, and a base in a reaction inert solvent
- Suitable activating agents include (benzot ⁇ azol-l-yloxy)t ⁇ s(d ⁇ methylam ⁇ no) phosphonium hexafluorophosphate or 1-(3-(d ⁇ methylam ⁇ nopropyl)-3-ethylcarbod ⁇ m ⁇ de hydrochlonde, preferably (benzot ⁇ azol-l-yloxy)t ⁇ s(d ⁇ methylam ⁇ no) phosphonium hexafluorophosphate
- Suitable bases include tertiary amines such as triethylamine, diisopropylethylamine or 4-N,N-d ⁇ methylam ⁇ nopy ⁇ d ⁇ ne, preferably triethylamine
- the temperature of the aforesaid reaction may range from about 0°
- the compound of formula III is prepared from a compound of formula IV by hydrogenolysis under an atmosphere of hydrogen in the presence of a catalyst in a reaction inert solvent
- Suitable catalysts include palladium or 5-10% palladium on activated charcoal, preferably 10% palladium on activated charcoal
- Suitable solvents include acetic acid, alcohols such as ethanol, methanol, or isopropanol, preferably ethanol
- the aforesaid reaction may be performed at a pressure from about 1 to about 5 atmospheres, preferably about 3 atmospheres Suitable temperatures for the aforesaid reaction range from about 20°C (room temperature) to about 60°C, preferably the temperature may range from about 20°C to about 25°C (i e room temperature)
- the reaction is complete within about 0 5 hours to about 24 hours, preferably about 3 hours
- Suitable oxidants include meta- chloroperbenzoic acid, hydrogen peroxide or sodium perborate, preferably meta- chloroperbenzoic acid
- Suitable solvents include halogenated solvents such as methylene chloride or chloroform, preferably methylene chloride
- Suitable temperatures for the aforesaid reaction range from about 0°C to about 60°C, preferably the temperature may range from about 20°C to about 25°C (i e room temperature) The reaction is complete within about 0 5 hours to about 24 hours, preferably about 3 hours
- Compounds of the formula V, wherein R 1 is hydroxy can be prepared from compounds of the formula VI by reaction with a Gngnard reagent and a thiol of the formula QSH in a reaction inert solvent
- Gngnard reagents include ethyl magnesium bromide or phenyl magnesium bromide, preferably ethyl magnesium bromide
- Suitable solvents include ethers such as diethy 1 ether, tetrahydrofuran or 1 ,2-d ⁇ methoxyethane, preferably the solvent is a mixture of tetrahydrofuran and diethyl ether
- Suitable temperatures for the aforesaid reaction are from about -78°C to about 50°C , preferably from about 0°C to about 25°C (i e room temperature) The reaction is complete in about 1 to about 24 hours, preferably about 3 hours Compounds of the formula V, wherein R 1 is (C 6 -C 10 )aryl(C
- Compounds of the formula VI can be prepared by methods well known to those of ordinary skill in the art Compounds of the formula VI can also be prepared by peracid oxidation (e g , meta-chloroperbenzoic acid) of the corresponding , ⁇ -unsaturated benzyl esters as described in Jerry March, Advanced Organic Chemistry. 735 (3rd ed , 1985)
- the corresponding , ⁇ -unsaturated benzyl esters may be prepared by Knovenagel condensation between a malonate monobenzyl ester and paraformaldehyde in the presence of pipendine as described in H O House, Modern Synthetic Reactions. 649-651 (2nd ed , WA Benjamin, Menlo Park, California, 1972)
- Scheme 2 refers to the preparation of compounds of the formula I, wherein R 2 is hydrogen and R 1 is OH
- compounds of formula I can be prepared from compounds of the formula VII by hydrogenolysis under an atmosphere of hydrogen in the presence of a catalyst in a reaction inert solvent
- Suitable catalysts include 5% palladium on barium sulfate or 5% palladium on carbon, preferably 5% palladium on barium sulfate
- Suitable solvents include an alcohol such as ethanol, methanol or isopropanol, preferably methanol
- the aforesaid reaction may be performed at a pressure from about 1 to about 5 atmospheres, preferably about 3 atmospheres
- Suitable temperatures for the aforesaid reaction range from about 20°C (room temperature) to about 60°C, preferably the temperature may range from about 20°C to about 25°C (i e room temperature)
- the reaction is complete within about 0 5 hours to about 5 hours, preferably about 3 hours
- the compound of formula IX is prepared from a compound of the formula X by reaction with an excess of sodium pe ⁇ odate in the presence of catalytic ruthenium trichloride hydrate
- the aforesaid reaction is conducted at a temperature from about 0°C to about 35°C, preferably from about 20°C to about 25°C (i e room temperature)
- Suitable solvents include acetone or a mixture of acetonitnle, carbon tetrachlo ⁇ de and water, preferably a 1 1 2 mixture of acetonitile, carbon tetrachlonde and water
- the reaction is conducted from about 0 5 to about 2 hours, preferably about 1 25 hours
- the compound of the formula X wherein "P" is pivaloyl, acetyl or benzoyl, is prepared by reaction of a compound of the formula XI with a protecting group reagent in the presence of a base in a reaction inert solvent
- Suitable protecting group reagents include pivaloyl chloride, pivaloic anhydride, acetyl chloride, acetic anhydride, benzoyl clo ⁇ de or benzoic anhydride, preferably acetic anhydride
- Suitable bases include tertiary amine bases such as pyridine or 4-N,N-d ⁇ methylam ⁇ nopyr ⁇ d ⁇ ne, preferably 4-N, N-dimethylaminopy ⁇ dine
- the temperature of the aforesaid reaction is from about 0°C to about 30°C, preferably from about 20°C to about 25°C (i e room temperature)
- Suitable solvents include halogenated solvents such as methylene chlor
- the compound of formula XI is prepared from a compound of the formula XII by reaction with 2-furaldehyde and a strong base in a polar aprotic solvent
- Suitable bases include potassium-tert -butoxide, lithium diisopropylamide, and butyl lithium, preferably 2 5 M n- butyllithium in hexane
- the temperature of the aforesaid reaction is from about -78°C to about 0°C, preferably about -78°C
- Suitable solvents include diethyl ether, tetrahydrofuran, or 1,2- dimethoxyethane, preferably the solvent is tetrahydrofuran
- the reaction is conducted from about 0 25 hours to about 6 hours, preferably about 0 33 hours
- the compound of formula XII is prepared from a compound of the formula XIII by reaction with an oxidant in a reaction inert solvent Suitable oxidants include meta- chloroperbenzoic acid
- the compound of the formula XIII is prepared from a compound of the formula XIV by reaction with a thiol of the formula QSH in the presence of a base in an aprotic solvent
- bases include sodium hydride, ethyl magnesium bromide, lithium diisopropyl amide, potassium hydride, or sodium methoxide, preferably sodium hydride
- the temperature of the aforesaid reaction is from about 0°C to about 60°C, preferably 20°C to about 25°C (i e room temperature)
- Suitable solvents include aprotic solvents such as methylene chloride, tetrahydrofuran or N,N-d ⁇ methylformam ⁇ de, preferably N,N-d ⁇ methylformam ⁇ de
- the reaction is conducted for about 1 hour to about 48 hours, preferably about 16 hours
- Compounds of the formula XIV and QSH are commercially available or can be made by methods well known to those of ordinary skill in the art
- Compounds of the formula QSH can also be prepared by reaction of an alkyl or aryl halide with sodium sulfhyd ⁇ de as described in Jerry March, Advanced Organic Chemistry. 360 and 589 (3rd ed , 1985)
- compounds of the formula QSH can also be prepared by reaction of an aryl diazonium salt with sodium sulfhydnde as described in March ⁇ d_ at 601
- compounds of the formula QSH can also be prepared by reaction of a Gngnard reagent with sulfur as described in March id.
- compounds of the formula QSH can also be prepared by reduction of a sulfonyl chloride, sulfonic acid or disulfide as described in March ⁇ d_ at 1107 and 1110
- Scheme 3 refers to the preparation of compounds of the formula I, wherein R 1 is other than hydroxy and R 2 is hydrogen
- compounds of the formula I are prepared from compounds of the formula XVII by hydrogenolysis according to methods analogous to the methods described for converting compounds of formula VII to compounds of formula I in Scheme 2
- compounds of the formula XVII are prepared from compounds of the formula XVI by reaction with O-benzylhydroxylamine hydrochlo ⁇ de in the presence of a catalyst and a base in a reaction inert solvent according to methods analogous to the conversion of compounds of the formula IX to formula VIII as described above in Scheme 2
- Compounds of the formula XVI are prepared from compounds of the formula XV by reaction with an excess of sodium periodate in the presence of a catalyst according to methods analogous to those used for the conversion of compounds of the formula X to formula IX as described above in Scheme 2.
- R 1 is (C 6 -C 10 )aryl(C C 6 )alkoxy or (C,-C e )alkoxy
- R 1a L is a leaving group and R 1a is (C 6 -C 10 )aryl(C 1 -C 6 )alkyl or (C 1 -C ⁇ )alky1, in the presence of a strong base in an aprotic polar solvent.
- Suitable leaving groups include chloro, fluoro, bromo, mesylate, triflate or tosylate.
- the leaving group is iodo.
- Suitable bases include lithium dialkyi amides such as lithium N-isopropyl-N-cyclohexylamide or lithium diisopropyl amide, potassium t-butoxide, sodium amide, potassium hydride or sodium hydride, preferably sodium hydride.
- Suitable solvents include ethers (such as THF, diethyl ether or 1 ,2-dimethoxyethane), preferably THF. The aforesaid reaction is conducted at about -78°C to about 0°C, preferably at about 0°C.
- Suitable leaving groups include chloro, fluoro, bromo or (R b )0- (i.e. an anhydride).
- the leaving group is chloro.
- Suitable bases include tertiary amine bases such as triethylamine, pyridine or 4-dimethylaminopyridine, preferably triethylamine.
- the temperature of the aforesaid reaction is from about 0°C to about 30°C, preferably from about 20°C to about 25°C (i.e. room temperature).
- Suitable solvents include halogenated solvents such as methylene chloride or chloroform, preferably methylene chloride. The reaction is conducted from about 1 hour to about 24 hours, preferably for about 2 hours.
- Scheme 4 refers to the preparation of compounds of the formula I, wherein R 2 is other than hydrogen and R 3 and R 4 are other than hydrogen.
- compounds of the formula I are prepared from compounds of the formula XXIII by hydrogenolysis under an atmosphere of hydrogen in the presence of a catalyst in a reaction inert solvent.
- Suitable catalysts include 5% palladium on barium sulfate or 5% palladium on carbon, preferably 5% palladium on barium sulfate.
- Suitable solvents include an alcohol such as ethanol, methanol or isopropanol, preferably methanol
- the aforesaid reaction may be performed at a pressure from about 1 to about 5 atmospheres, preferably about 3 atmospheres
- Suitable temperatures for the aforesaid reaction range from about 20°C (room temperature) to about 60°C, preferably the temperature may range from about 20°C to about 25°C (i e room temperature)
- the reaction is complete within about U 5 hours to about 5 hours, preferably about 3 hours
- the compound of the formula XXIII is prepared from a compound of the formula XXII by reaction with O-benzylhydroxylamine hydrochlonde in the presence of a catalyst and a base in a reaction inert solvent
- Suitable catalysts include (benzotr ⁇ azol-1- yloxy)t ⁇ s(d ⁇ methylam ⁇ no)phosphon ⁇ um hexafluorophosphate or 1-(3-(d ⁇ methylam ⁇ nopropyl)-3- ethylcarbodiimide hydrochlonde, preferably (benzot ⁇ azol-l-yloxy)tr ⁇ s(d ⁇ methylam ⁇ no) phosphonium hexafluorophosphate
- Suitable bases include tertiary amines such as triethylamine diisopropylethylamine or dimethylaminopy ⁇ dine, preferably triethylamine
- the aforesaid reaction temperature is from about 0° C to about
- the compound of the formula XXII can be prepared by deprotection of a compound of the formula XXI by reaction with an alkali metal hydroxide in a polar solvent
- Suitable alkali metal hydroxides include lithium hydroxide, sodium hydroxide or potassium hydroxide, preferably lithium hydroxide, most preferably about 5 equivalents of the alkali metal hydroxide
- the aforesaid reaction may conducted at a temperature from about 0°C to about 60°C, preferably from about 20°C to about 25°C (i e room temperature)
- Suitable solvents include a mixture of water and an alcohol such as methanol or ethanol and, optionally an water miscible ether such as tetrahydrofuran or 1 ,2-d ⁇ methoxyethane
- the solvent system is methanol/water/tetrahydrofuran
- the reaction is conducted from about 1 to about 72 hours, preferably about 24 hours
- Suitable bases include sodium hydride (NaH), potassium-tert -butoxide, lithium d ⁇ sopropylamide, and butyl lithium, preferably 2 5 M n-butyllithium in hexane
- NaH sodium hydride
- potassium-tert -butoxide lithium d ⁇ sopropylamide
- butyl lithium preferably 2 5 M n-butyllithium in hexane
- the temperature of the aforesaid reaction is from about -78°C to about 0°C, preferably about -78°C
- Suitable solvents include diethyl ether, tetrahydrofuran, or 1 ,2-d ⁇ methoxyethane, preferably the solvent is tetrahydrofuran
- the reaction is conducted from about 0 25 hours to about 6 hours, preferably about 0 33 hours
- compounds of the formula I wherein R 1 is other than hydroxy, R 2 is other than hydrogen and R and R 4 are other than hydrogen, can be prepared from compounds of the formula XXV by methods analogous to the conversion of compounds of the formula XXII to compounds of formula I, as described above in Scheme 4 Compounds of the formula XXV can be prepared from compounds of the formula
- Suitable catalysts include palladium or 5- 10% palladium on activated charcoal, preferably 10% palladium on activated charcoal
- Suitable solvents include acetic acid, alcohols such as ethanol, methanol, or isopropanol, preferably ethanol
- the aforesaid reaction may be performed at a pressure from about 1 to about 5 atmospheres, preferably about 3 atmospheres Suitable temperatures for the aforesaid reaction range from about 20°C (room temperature) to about 60°C, preferably the temperature may range from about 20°C to about 25°C (i e room temperature)
- the reaction is complete within about 0 5 hours to about 24 hours, preferably about 3 hours
- (C r C 6 )alkoxy can be prepared from compounds of the formula XXI by reaction with an arylalkyl or alkyl halide in the presence of a base in an aprotic solvent
- bases include sodium hydride, ethyl magnesium bromide, lithium diisopropyl amide, potassium hydride, or sodium methoxide, preferably sodium hydride
- the temperature of the aforesaid reaction is from about 0°C to about 60°C, preferably 20°C to about 25°C (i e room temperature)
- Suitable solvents include aprotic solvents such as methylene chloride, tetrahydrofuran or N,N- dimethylformamide, preferably N,N-d ⁇ methylformam ⁇ de
- the reaction is conducted for about 1 hour to about 48 hours, preferably about 16 hours
- Suitable bases include tertiary amines such as triethylamine, dnsopropylethylamine or 4-N,N-d ⁇ methylam ⁇ nopyr ⁇ d ⁇ ne, preferably triethylamine
- the temperature of the aforesaid reaction may range from about 0°C to about 60°C, preferably about 20°C (room temperature)
- Suitable solvents include halogenated solvents such as methylene chloride or chloroform, or ethers such as THF or diethyl ether, preferably the solvent is methylene chloride
- the acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, ]_ ⁇ _, salts containing pharmacologically acceptable anions, such as hydrochlonde, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [ ⁇ _e_, 1 ,1'-methylene-b ⁇ s-(2-hydroxy-3- naphthoate)] salts
- pharmacologically acceptable anions such as hydrochlonde, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate
- Those compounds of the formula I which are also acidic in nature, are capable of forming base salts with various pharmacologically acceptable cations
- examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts
- These salts are all prepared by conventional techniques
- the chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the herein described acidic compounds of formula I
- These non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc
- These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating
- the compounds of formula I or their pharmaceutically acceptable salts (hereinafter also referred to as the compounds of the present invention) to inhibit matrix metalloproteinases or the production of tumor necrosis factor (TNF) and, consequently, demonstrate their effectiveness for treating diseases characterized by matrix metalloproteinase or the production of tumor necrosis factor is shown by the following yjtro assay tests
- MMP-1 Human Colla ⁇ enase
- Human recombinant collagenase is activated with trypsin using the following ratio 10 mg trypsin per 100 mg of collagenase
- the trypsin and collagenase are incubated at room temperature for 10 minutes then a five fold excess (50 mg/10 mg trypsin) of soybean trypsin inhibitor is added 10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted using the following Scheme
- Collagenase is diluted to 400 ng/ml and 25 ml is then added to appropriate wells of the microfluor plate Final concentration of collagenase in the assay is 100 ng/ml
- Substrate (DNP-Pro-Cha-Gly-Cys(Me)-H ⁇ s-Ala-Lys(NMA)-NH 2 ) is made as a 5 mM stock in dimethyl sulfoxide and then diluted to 20 mM in assay buffer The assay is initiated by the addition of 50 ml substrate per well of the microfluor plate to give a final concentration of 10 mM
- Fluorescence readings (360 nM excitation, 460 nm emission) were taken at time 0 and then at 20 minute intervals The assay is conducted at room temperature with a typical assay time of 3 hours
- Fluorescence vs time is then plotted for both the blank and collagenase containing samples (data from triplicate determinations is averaged)
- a time point that provides a good signal (the blank) and that is on a linear part of the curve (usually around 120 minutes) is chosen to determine IC 50 values
- the zero time is used as a blank for each compound at each concentration and these values are subtracted from the 120 minute data
- Data is plotted as inhibitor concentration vs % control (inhibitor fluorescence divided by fluorescence of collagenase alone x 100)
- IC 50 's are determined from the concentration of inhibitor that gives a signal that is 50% of the control
- IC 50 's are reported to be ⁇ 0 03 mM then the inhibitors are assayed at concentrations of 0 3 mM, 0 03 mM, 0 03 mM and 0 003 mM
- MMP-2 Inhibition of Gelatmase activity is assayed using the Dnp-Pro-Cha-Gly-Cys(Me)-H ⁇ s-Ala- Lys(NMA)-NH 2 substrate (10 mM) under the same conditions as inhibition of human collagenase (MMP-1)
- 72kD gelatmase is activated with 1 mM APMA (p-aminophenyl mercuric acetate) for 15 hours at 4°C and is diluted to give a final concentration in the assay of 100 mg/ml
- Inhibitors are diluted as for inhibition of human collagenase (MMP-1) to give final concentrations in the assay of 30 mM, 3 mM, 0 3 mM and 0 03 mM Each concentration is done in triplicate
- Fluorescence readings (360 nm excitation, 460 emission) are taken at time zero and then at 20 minutes intervals for 4 hours
- IC 50 's are determined as per inhibition of human collagenase (MMP-1 ) If IC 50 's are reported to be less than 0 03 mM, then the inhibitors are assayed at final concentrations of 0 3 mM, 0 03 mM, 0 003 mM and 0 003 mM
- MMP-3 Inhibition of Stromelysin Activity
- Inhibition of stromelysin activity is based on a modified spectrophotometric assay described by Weingarten and Feder (Wemberg, H and Feder, J , Spectrophotometric Assay for Vertebrate Collagenase, Anal Biochem 147, 437-440 (1985))
- Hydrolysis of the thio peptolide substrate [Ac-Pro-Leu-Gly-SCH[CH 2 CH(CH 3 ) 2 ]CO-Leu-Gly-OC 2 H 5 ] yields a mercaptan fragment that can be monitored in the presence of Ellman's reagent
- Human recombinant prostromelysin is activated with trypsin using a ratio of 1 ml of a 10 mg/ml trypsin stock per 26 mg of stromelysin The trypsin and stromeiysin are incubated at 37°C for 15 minutes followed by 10
- Assays are conducted in a total volume of 250 ml of assay buffer (200 mM sodium chloride, 50 mM MES, and 10 mM calcium chloride, pH 6 0) in 96-well microliter plates
- Activated stromelysin is diluted in assay buffer to 25 mg/ml
- Ellman's reagent (3-Carboxy-4- nitrophenyl disulfide) is made as a 1M stock in dimethyl formamide and diluted to 5 mM in assay buffer with 50 ml per well yielding at 1 mM final concentration 10 mM stock solutions of inhibitors are made in dimethyl sulfoxide and diluted serially in assay buffer such that addition of 50 mL to the appropriate wells yields final concentrations of 3 mM, 0 3 mM, 0 003 mM, and 0 0003 mM All conditions are completed in triplicate
- a 300 mM dimethyl sulfoxide stock solution of the peptide substrate is diluted to 15 mM in assay buffer and the assay is initiated by addition of 50 ml to each well to give a final concentration of 3 mM substrate Blanks consist of the peptide substrate and Ellman's reagent without the enzyme Product formation was monitored at 405 nm with a Molecular Devices
- MMP-13 Human recombinant MMP-13 is activated with 2mM APMA (p-aminophenyl mercuric acetate) for 1 5 hours, at 37°C and is diluted to 400 mg/ml in assay buffer (50 mM Tns, pH 7 5, 200 mM sodium chloride, 5mM cal ⁇ um chloride, 20mM zinc chloride, 0 02% b ⁇ j) Twenty-five microliters of diluted enzyme is added per well of a 96 well microfluor plate The enzyme is then diluted in a 1 4 ratio in the assay by the addition of inhibitor and substrate to give a final concentration in the assay of 100 mg/ml
- assay buffer 50 mM Tns, pH 7 5, 200 mM sodium chloride, 5mM cal ⁇ um chloride, 20mM zinc chloride, 0 02% b ⁇ j
- 10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted in assay buffer as per the inhibitor dilution scheme for inhibition of human collagenase (MMP-1) Twenty-five microliters of each concentration is added in triplicate to the microfluor plate The final concentrations in the assay are 30 mM, 3mM, 0 3 mM, and 0 03 mM Substrate (Dnp-Pro-Cha-Gly-Cys(Me)-H ⁇ s-Ala-Lys(NMA)-NH 2 ) is prepared as for inhibition of human collagenase (MMP-1) and 50 ml is added to each well to give a final assay concentration of 10 mM Fluorescence readings (360 nM excitation, 450 emission) are taken at time 0 and every 5 minutes for 1 hour
- Positive controls consist of enzyme and substrate with no inhibitor and blanks consist of substrate only
- IC 50 's are determined as per inhibition of human collagenase (MMP-1) If IC 50 's are reported to be less than 0 03 mM, inhibitors are then assayed at final concentrations of 0 3 mM, 0 03 mM, 0 003 mM and 0 0003 mM
- the active compound will be administered at dosages between about 0 1 and 25 mg/kg body weight of the subject to be treated per day, preferably from about 0 3 to 5 mg/kg
- the active compound will be administered orally or parenterally
- some variation in dosage will necessarily occur depending on the condition of the subject being treated
- the person responsible for administration will, in any event, determine the appropriate dose for the individual subject
- the compounds of the present invention can be administered in a wide variety of different dosage forms, in general, the therapeutically effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5 0% to about 70% by weight
- tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrro done, sucrose, gelation and acacia Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tablettmg purposes
- Solid compositions of a similar type may also be employed as fillers in gelatin capsules, preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols
- the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents as well
- a sterile mjectable solution of the active ingredient is usually prepared Solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed The aqueous solutions should be suitably adjusted and buffered, preferably at a pH of greater than 8, if necessary and the liquid diluent first rendered isotonic These aqueous solutions are suitable intravenous injection purposes
- the oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes
- the preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art
- compounds can be administered intramuscularly or subcutaneously at dosage levels of about 0 1 to 50 mg/kg/day, advantageously 0 2 to 10 mg/kg/day given in a single dose or up to 3 divided doses
- the active compounds of the invention may also be formulated in rectal compositions such as supposi
- the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e g .
- the dosage unit may be determined by providing a valve to deliver a metered amount
- the pressurized container or nebulizer may contain a solution or suspension of the active compound
- Capsules and cartridges made, for example, from gelatin
- an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch
- Example 4 2.N-DIHYDROXY-2-f1-(4-METHOXYBENZENESULFONYL)CYCLOPENTYL1ACETAMlDE 2,N-Dihydroxy-2-[1-(4-methoxybenzenesulfonyl)cyclopentyl]acetamide was prepared by a method analogous to that described in Example 3 using 4-methoxybenzenethiol and cyclopentyl bromide as startinc* materials. MS m/z 328 (M-1).
- DIHYDROXYACETAMIDE 2- ⁇ 1-[4-(4-Fluorophenoxy)benzenesulfonyl]cyclobutyl ⁇ -2,N-dihydroxyacetamide was prepared by a method analogous to that described in Example 3 using 4-(4- fluorophenoxy)benzenethiol and cyclobutyl bromide as starting materials. MS m/z 394 (M-1).
- 4-(4-Fluorophenoxy)benzenethiol was obtained as follows. Chlorosulfonic acid (26 mL, 0.392 mole) was added dropwise to ice-cooled 4-fluorophenoxybenzene (36.9 grams, 0.196 mole) with mechanical stirring. When addition was complete, the mixture was stirred at room temperature for 4 hours. The mixture was then poured into ice water. The product, 4-
- DIHYDROXYACETAMIDE 2- ⁇ 1-[4-(4-Fluorophenoxy)benzenesulfonyl]cyclopentyl ⁇ -2,N-d ⁇ hydroxyacetam ⁇ de was prepared by a method analogous to that described in Example 3 using (4- fluorophenoxy)benzeneth ⁇ ol and cyclopentyl bromide as starting materials MS m/z 408 (M-1)
Abstract
L'invention porte sur un composé de formule (I) dans laquelle R?1, R2, R3, R4¿ et Q sont définis dans la description, sur des préparations pharmaceutiques le contenant, et sur leur utilisation à des fins médicales comme inhibiteurs des métalloprotéases matrices et générateurs du facteur de nécrose tumorale (TNF).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3740297P | 1997-02-07 | 1997-02-07 | |
US37402P | 1997-02-07 | ||
PCT/IB1998/000101 WO1998034915A1 (fr) | 1997-02-07 | 1998-01-27 | Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0966438A1 true EP0966438A1 (fr) | 1999-12-29 |
Family
ID=21894150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98900334A Withdrawn EP0966438A1 (fr) | 1997-02-07 | 1998-01-27 | Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0966438A1 (fr) |
JP (1) | JP2000507975A (fr) |
AP (1) | AP9801169A0 (fr) |
AR (1) | AR011116A1 (fr) |
AU (1) | AU5493598A (fr) |
BR (1) | BR9807824A (fr) |
CA (1) | CA2279863A1 (fr) |
HR (1) | HRP980062A2 (fr) |
MA (1) | MA26472A1 (fr) |
PA (1) | PA8446001A1 (fr) |
TN (1) | TNSN98022A1 (fr) |
WO (1) | WO1998034915A1 (fr) |
ZA (1) | ZA98970B (fr) |
Families Citing this family (255)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6362183B1 (en) | 1997-03-04 | 2002-03-26 | G. D. Searle & Company | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
EA199900792A1 (ru) * | 1997-03-04 | 2000-04-24 | Монсанто Компани | Сульфонильные двухвалентные арильные или гетероарильные соединения гидроксамовой кислоты |
TR200001391T2 (tr) | 1997-11-21 | 2000-11-21 | Pharmacia & Upjohn Company | Matris metaloproteinaz önleyicileri olarak beta-sülfonil hidroksamik asitlerin alfa-hidroksi, -amino ve halo türevleri. |
US6191300B1 (en) | 1999-04-16 | 2001-02-20 | Eastman Chemical Company | Process for the preparation of cyclopropylacetonitrile |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
PE20020801A1 (es) | 2001-01-05 | 2002-09-06 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
AU2002345792A1 (en) | 2001-06-21 | 2003-01-08 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
EP1483268A2 (fr) | 2002-03-01 | 2004-12-08 | Pfizer Inc. | Derives indolyl-uree de thienopyridines utilises comme agents antiangiogeniques, et leurs methodes d'utilisation |
AR038971A1 (es) | 2002-03-13 | 2005-02-02 | Array Biopharma Inc | Derivados de bencimidazol n3 alquilado como inhibidores de mek |
UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
RS20050430A (en) | 2002-12-19 | 2007-08-03 | Pfizer Inc., | 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases |
BRPI0407827B8 (pt) | 2003-02-26 | 2021-05-25 | Sugen Inc | compostos de aminoeteroarila como inibidores de proteína cinase e respectivos usos |
WO2005021554A1 (fr) | 2003-08-29 | 2005-03-10 | Pfizer Inc. | Thienopyridine-phenylacetamides et leurs derives utiles comme nouveaux agents anti-angiogeniques |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
PT2251327E (pt) | 2003-11-19 | 2014-03-04 | Array Biopharma Inc | Inibidores heterocíclicos de mek |
PL1786785T3 (pl) | 2004-08-26 | 2010-08-31 | Pfizer | Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
CN102304086B (zh) | 2005-05-18 | 2013-12-04 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
US7820664B2 (en) | 2007-01-19 | 2010-10-26 | Bayer Schering Pharma Ag | Inhibitors of MEK |
US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
ES2374450T3 (es) | 2005-09-20 | 2012-02-16 | OSI Pharmaceuticals, LLC | Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina. |
TWI405756B (zh) | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
US7842836B2 (en) | 2006-04-11 | 2010-11-30 | Ardea Biosciences | N-aryl-N'alkyl sulfamides as MEK inhibitors |
EP2012786B1 (fr) | 2006-04-18 | 2010-10-06 | Ardea Biosciences, Inc. | Sulfonamides pyridone et sulfamides pyridone en tant qu'inhibiteurs de mek |
JP2010513263A (ja) | 2006-12-15 | 2010-04-30 | ファイザー・プロダクツ・インク | ベンズイミダゾール誘導体 |
JP4782239B2 (ja) | 2007-04-18 | 2011-09-28 | ファイザー・プロダクツ・インク | 異常細胞増殖治療のためのスルホニルアミド誘導体 |
US8530463B2 (en) | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
CA2694646C (fr) | 2007-07-30 | 2017-09-05 | Ardea Biosciences, Inc. | Combinaisons d'inhibiteurs de mek et d'inhibiteurs de raf kinase et leurs utilisations |
DK2222675T3 (da) | 2007-12-19 | 2013-11-04 | Genentech Inc | 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse |
JP5710269B2 (ja) | 2007-12-21 | 2015-04-30 | ジェネンテック, インコーポレイテッド | アザインドリジン類と使用方法 |
SG10201605472WA (en) | 2008-01-04 | 2016-09-29 | Intellikine Llc | Certain Chemical Entities, Compositions And Methods |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US8895546B2 (en) | 2009-03-27 | 2014-11-25 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
US20090258865A1 (en) | 2008-03-28 | 2009-10-15 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
KR20110039326A (ko) | 2008-07-08 | 2011-04-15 | 인텔리카인, 인크. | 키나제 억제제 및 사용 방법 |
JP5836125B2 (ja) | 2008-10-16 | 2015-12-24 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用 |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
NZ594177A (en) | 2009-02-05 | 2014-02-28 | Immunogen Inc | Novel benzodiazepine derivatives |
EP2393814A1 (fr) | 2009-02-09 | 2011-12-14 | SuperGen, Inc. | Inhibiteurs pyrrolopyrimidinyle de l'axi kinase |
EP2400985A2 (fr) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Thérapie anti-cancer combinée |
JP2012519170A (ja) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法 |
WO2010099363A1 (fr) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation |
WO2010099138A2 (fr) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation |
EP2401613A2 (fr) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation |
TW201035088A (en) | 2009-02-27 | 2010-10-01 | Supergen Inc | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
CN106478496A (zh) | 2009-03-27 | 2017-03-08 | 阿迪生物科学公司 | 作为mek抑制剂的二氢吡啶磺酰胺和二氢吡啶硫酰胺 |
EP2427195B1 (fr) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Composés hétérocycliques et leurs utilisations |
WO2011014726A1 (fr) | 2009-07-31 | 2011-02-03 | Osi Pharmaceuticals, Inc. | Polythérapie par inhibiteur de mtor et inhibiteur de langiogenèse |
CA2771532C (fr) | 2009-08-17 | 2021-03-23 | Intellikine, Inc. | Composes heterocycliques et leurs utilisations |
JP2013503846A (ja) | 2009-09-01 | 2013-02-04 | ファイザー・インク | ベンズイミダゾール誘導体 |
ES2534358T3 (es) | 2009-10-13 | 2015-04-21 | Allomek Therapeutics, Llc | Inhibidores novedosos de MEK útiles en el tratamiento de enfermedades |
WO2011049625A1 (fr) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Procédé de criblage d'aflatoxine dans des produits |
SG10201500895XA (en) | 2009-11-05 | 2015-04-29 | Rhizen Pharmaceuticals Sa | Chromen-4-one Derivatives As Kinase Modulators |
AU2011215900A1 (en) | 2010-02-10 | 2012-07-26 | Immunogen, Inc. | CD20 antibodies and uses thereof |
MX343383B (es) | 2010-02-12 | 2016-11-03 | Pfizer Inc * | Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3, 4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona. |
US20110275644A1 (en) | 2010-03-03 | 2011-11-10 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
WO2011109584A2 (fr) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1 |
CN103068824B (zh) | 2010-05-17 | 2017-09-08 | 印蔻真治疗公司 | 作为蛋白激酶调节剂的新型3,5‑二取代‑3h‑咪唑并[4,5‑b]吡啶和3,5‑二取代‑3h‑[1,2,3]***并[4,5‑b]吡啶化合物 |
WO2011146882A1 (fr) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Composés chimiques, compositions et procédés pour modulation de kinases |
EP2582727B8 (fr) | 2010-06-16 | 2017-04-19 | University of Pittsburgh- Of the Commonwealth System of Higher Education | Anticorps dirigés contre l'endoplasmine et leur utilisation |
US9056865B2 (en) | 2010-10-20 | 2015-06-16 | Pfizer Inc. | Pyridine-2-derivatives as smoothened receptor modulators |
CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
AR084824A1 (es) | 2011-01-10 | 2013-06-26 | Intellikine Inc | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas |
AU2012212075A1 (en) | 2011-02-02 | 2013-07-18 | Amgen Inc. | Methods and compositons relating to inhibition of IGF-1R |
US9353127B2 (en) | 2011-02-15 | 2016-05-31 | Immunogen, Inc. | Methods of preparation of conjugates |
WO2012116040A1 (fr) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de la kinase du récepteur du facteur de croissance 1 analogue à l'insuline dans le carcinome hépatocellulaire |
WO2012116237A2 (fr) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Composés hétérocycliques et leurs utilisations |
US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
US20140178368A1 (en) | 2011-04-19 | 2014-06-26 | Leslie Lynne SHARP | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
WO2012149014A1 (fr) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer |
CA2833935C (fr) | 2011-05-04 | 2020-09-15 | Dhanapalan Nagarathnam | Nouveaux composes en tant que modulateurs de proteines kinases |
CA2842190A1 (fr) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Composes heterocycliques et leurs utilisations |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
PL3409278T3 (pl) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocykliczne inhibitory kinazy białkowej |
RU2014111823A (ru) | 2011-08-29 | 2015-10-10 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
JP5914667B2 (ja) | 2011-09-22 | 2016-05-11 | ファイザー・インク | ピロロピリミジンおよびプリン誘導体 |
WO2013049332A1 (fr) | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibiteurs de monoacylglycérol lipase et procédés de leur utilisation |
ES2654160T3 (es) | 2011-10-04 | 2018-02-12 | Igem Therapeutics Limited | Anticuerpos de IgE anti-HMW-MAA |
RU2014114015A (ru) | 2011-11-08 | 2015-12-20 | Пфайзер Инк. | Способы лечения воспалительных расстройств с использованием антител против m-csf |
EP3345624A1 (fr) | 2012-02-22 | 2018-07-11 | The Regents Of The University Of Colorado | Dérivés de bouvardin et leurs utilisations thérapeutiques |
US9452215B2 (en) | 2012-02-22 | 2016-09-27 | The Regents Of The University Of Colorado | Bourvadin derivatives and therapeutic uses thereof |
KR102164317B1 (ko) | 2012-03-30 | 2020-10-13 | 리젠 파마슈티컬스 소시에떼 아노님 | C-met 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물 |
WO2013152252A1 (fr) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Polythérapie antinéoplasique |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3505534A1 (fr) | 2012-06-08 | 2019-07-03 | Sutro Biopharma, Inc. | Anticorps comprenant des résidus d'acides aminés non endogènes spécifiques d'un site, leurs procédés de préparation et leurs procédés d'utilisation |
US9732161B2 (en) | 2012-06-26 | 2017-08-15 | Sutro Biopharma, Inc. | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
WO2014031566A1 (fr) | 2012-08-22 | 2014-02-27 | Immunogen, Inc. | Dérivés de benzodiazépine cytotoxique |
PL3584255T3 (pl) | 2012-08-31 | 2022-05-16 | Sutro Biopharma, Inc. | Modyfikowane aminokwasy zawierające grupę azydkową |
ES2644758T3 (es) | 2012-10-16 | 2017-11-30 | Tolero Pharmaceuticals, Inc. | Moduladores de PKM2 y métodos para su uso |
LT2914296T (lt) | 2012-11-01 | 2018-09-25 | Infinity Pharmaceuticals, Inc. | Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius |
WO2014134486A2 (fr) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques |
US9999680B2 (en) | 2013-02-28 | 2018-06-19 | Immunogen, Inc. | Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents |
ES2738493T3 (es) | 2013-03-14 | 2020-01-23 | Tolero Pharmaceuticals Inc | Inhibidores de JAK2 y ALK2 y métodos para su uso |
US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
CA2904393A1 (fr) | 2013-03-15 | 2014-09-25 | Araxes Pharma Llc | Inhibiteurs covalents de k-ras g12c |
UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
WO2014151386A1 (fr) | 2013-03-15 | 2014-09-25 | Infinity Pharmaceuticals, Inc. | Sels et formes solides d'isoquinolinones et compositions les comprenant et procédés pour les utiliser |
JP2016512835A (ja) | 2013-03-15 | 2016-05-09 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせ及びそれらの使用 |
AU2014273946B2 (en) | 2013-05-30 | 2020-03-12 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
WO2014194030A2 (fr) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques |
US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
EP3363800A1 (fr) | 2013-10-03 | 2018-08-22 | Kura Oncology, Inc. | Inhibiteurs hétérocycliques d'erk et procédés d'utilisation |
MY175778A (en) | 2013-10-04 | 2020-07-08 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
WO2015051241A1 (fr) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
EP3636639A1 (fr) | 2013-10-10 | 2020-04-15 | Araxes Pharma LLC | Inhibiteurs de kras g12c |
US9840493B2 (en) | 2013-10-11 | 2017-12-12 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
WO2015061204A1 (fr) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
WO2015155624A1 (fr) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dérivés de dihydropyrrolopyrimidine |
WO2015168079A1 (fr) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Dérivés de pyrimidine ou de pyridine utiles en tant qu'inhibiteurs de pi3k |
JP6574203B2 (ja) | 2014-04-30 | 2019-09-11 | ファイザー・インク | シクロアルキル結合ジヘテロ環誘導体 |
AP2017009690A0 (en) | 2014-06-19 | 2017-01-31 | Ariad Pharma Inc | Heteroaryl compounds for kinase inhibition |
WO2016001789A1 (fr) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer |
US10934360B2 (en) | 2014-07-31 | 2021-03-02 | The Hong Kong University Of Science And Technology | Human monoclonal antibodies against EPHA4 and their use |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
WO2016049524A1 (fr) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Inhibiteurs de protéines mutantes kras g12c |
EP3233829B1 (fr) | 2014-12-18 | 2019-08-14 | Pfizer Inc | Dérivés de pyrimidine et de triazine, et leur utilisation comme inhibiteurs d'axl |
EA201792214A1 (ru) | 2015-04-10 | 2018-01-31 | Араксис Фарма Ллк | Соединения замещенного хиназолина |
JP6789239B2 (ja) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Krasの縮合三環系インヒビターおよびその使用の方法 |
WO2016172214A1 (fr) | 2015-04-20 | 2016-10-27 | Tolero Pharmaceuticals, Inc. | Prédiction de la réaction à l'alvocidib par identification de profil mitochondrial |
EP3288957A4 (fr) | 2015-05-01 | 2019-01-23 | Cocrystal Pharma, Inc. | Analogues de nucléosides à utiliser pour le traitement d'infections par des virus de la famille des flaviviridae et du cancer |
KR102608921B1 (ko) | 2015-05-18 | 2023-12-01 | 스미토모 파마 온콜로지, 인크. | 생체 이용률이 증가된 알보시딥 프로드러그 |
WO2016197027A1 (fr) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll |
TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
WO2017009751A1 (fr) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Dérivés de pyrimidine |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
KR20180034538A (ko) | 2015-08-03 | 2018-04-04 | 톨레로 파마수티컬스, 인크. | 암의 치료를 위한 병행 요법 |
WO2017058768A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines kras portant la mutation g12c |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356354A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines kras portant la mutation g12c |
WO2017058792A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines kras portant la mutation g12c |
WO2017058902A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines mutantes kras g12c |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017070256A2 (fr) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Méthode de criblage d'inhibiteurs de ras |
AU2016355433C1 (en) | 2015-11-16 | 2021-12-16 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
EA201891304A1 (ru) | 2015-12-03 | 2019-01-31 | Агиос Фармасьютикалс, Инк. | ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ |
US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
CA3011455A1 (fr) | 2016-01-27 | 2017-08-03 | Sutro Biopharma, Inc. | Conjugues d'anticorps anti-cd74, compositions comprenant des conjugues d'anticorps anti-cd74 et methodes d'utilisations desdits conjugues d'anticorps anti-cd74 |
TWI743096B (zh) | 2016-03-16 | 2021-10-21 | 美商庫拉腫瘤技術股份有限公司 | Menin-mll之橋聯雙環抑制劑及使用方法 |
PT3429591T (pt) | 2016-03-16 | 2023-06-21 | Univ Michigan Regents | Derivados de tieno[2,3-d]pirimidina substituídos como inibidores de menina-llm e métodos de utilização |
US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
ES2910787T3 (es) | 2016-05-12 | 2022-05-13 | Univ Michigan Regents | Inhibidores de ASH1L y métodos de tratamiento con los mismos |
US11118233B2 (en) | 2016-05-18 | 2021-09-14 | The University Of Chicago | BTK mutation and ibrutinib resistance |
WO2017214269A1 (fr) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
CA3035081A1 (fr) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition et methodes de traitement des dereglements des lymphocytes b |
US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
JP2019534260A (ja) | 2016-10-07 | 2019-11-28 | アラクセス ファーマ エルエルシー | Rasの阻害剤としての複素環式化合物およびその使用方法 |
US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
WO2018098352A2 (fr) | 2016-11-22 | 2018-05-31 | Jun Oishi | Ciblage d'expression du point de contrôle immunitaire induit par kras |
US10132797B2 (en) | 2016-12-19 | 2018-11-20 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
BR112019012976A2 (pt) | 2016-12-22 | 2019-12-31 | Amgen Inc | inibidores de kras g12c e métodos de uso dos mesmos |
WO2018140513A1 (fr) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer |
US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
AU2018213718B2 (en) | 2017-01-26 | 2022-08-25 | Zlip Holding Limited | CD47 antigen binding unit and uses thereof |
WO2018140599A1 (fr) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Composés à base de benzothiophène et de benzothiazole et leurs procédés d'utilisation |
CN110382483A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的n-杂环化合物及其使用方法 |
JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法 |
CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液***恶性肿瘤和尤因肉瘤的方法 |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
KR20200010306A (ko) | 2017-05-25 | 2020-01-30 | 아락세스 파마 엘엘씨 | Kras의 공유적 억제제 |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
US20200207859A1 (en) | 2017-07-26 | 2020-07-02 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
SG11202001499WA (en) | 2017-09-08 | 2020-03-30 | Amgen Inc | Inhibitors of kras g12c and methods of using the same |
US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
EP3684814A1 (fr) | 2017-09-18 | 2020-07-29 | Sutro Biopharma, Inc. | Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations |
TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
WO2019075367A1 (fr) | 2017-10-13 | 2019-04-18 | Tolero Pharmaceuticals, Inc. | Activateurs de pkm2 en combinaison avec des espèces réactives de l'oxygène pour le traitement du cancer |
CN111655257A (zh) | 2017-11-10 | 2020-09-11 | 密歇根大学董事会 | Ash1l抑制剂及用其进行治疗的方法 |
CA3084809A1 (fr) | 2017-12-07 | 2019-06-13 | The Regents Of The University Of Michigan | Inhibiteurs de la famille nsd et methodes de traitement comprenant ces derniers |
US11013741B1 (en) | 2018-04-05 | 2021-05-25 | Sumitomo Dainippon Pharma Oncology, Inc. | AXL kinase inhibitors and use of the same |
EP3788053A1 (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
AU2019262589B2 (en) | 2018-05-04 | 2022-07-07 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
JP7361720B2 (ja) | 2018-05-10 | 2023-10-16 | アムジエン・インコーポレーテツド | がんの治療のためのkras g12c阻害剤 |
US11096939B2 (en) | 2018-06-01 | 2021-08-24 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
US11319302B2 (en) | 2018-06-07 | 2022-05-03 | The Regents Of The University Of Michigan | PRC1 inhibitors and methods of treatment therewith |
MX2020012204A (es) | 2018-06-11 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c para tratar el cáncer. |
MX2020012261A (es) | 2018-06-12 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. |
CA3103995A1 (fr) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Procedes de traitement de maladies associees a l'expression anormale d'acvr1 et inhibiteurs d'acvr1 destines a etre utilises dans ceux-ci |
MX2021000887A (es) | 2018-08-01 | 2021-03-31 | Araxes Pharma Llc | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. |
WO2020060944A1 (fr) | 2018-09-17 | 2020-03-26 | Sutro Biopharma, Inc. | Polythérapies avec des conjugués d'anticorps anti-récepteur du folate |
US20210380595A1 (en) | 2018-10-24 | 2021-12-09 | Araxes Pharma Llc | 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of g12c mutant kras protein for inhibiting tumor metastasis |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
MA55136A (fr) | 2018-11-19 | 2022-02-23 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
CA3120383A1 (fr) | 2018-11-29 | 2020-06-04 | Araxes Pharma Llc | Composes et procedes d'utilisation associes pour le traitement du cancer |
EP3890749A4 (fr) | 2018-12-04 | 2022-08-03 | Sumitomo Dainippon Pharma Oncology, Inc. | Inhibiteurs de cdk9 et leurs polymorphes destinés à être utilisés en tant qu'agents pour le traitement du cancer |
CA3123044A1 (fr) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Amides d'heteroaryle utiles en tant qu'inhibiteurs de kif18a |
WO2020132651A1 (fr) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Inhibiteurs de kif18a |
JOP20210154B1 (ar) | 2018-12-20 | 2023-09-17 | Amgen Inc | مثبطات kif18a |
CA3123227A1 (fr) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Amides d'heteroaryle utiles en tant qu'inhibiteurs de kif18a |
WO2020167990A1 (fr) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprenant des inhibiteurs de protéine kinase hétérocycliques |
US20230096028A1 (en) | 2019-03-01 | 2023-03-30 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
US20230148450A9 (en) | 2019-03-01 | 2023-05-11 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置 |
EP3941463A1 (fr) | 2019-03-22 | 2022-01-26 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprenant des modulateurs de pkm2 et méthodes de traitement les utilisant |
US20220362394A1 (en) | 2019-05-03 | 2022-11-17 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
EP3738593A1 (fr) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosage d'inhibiteur de kras pour le traitement de cancers |
CR20210665A (es) | 2019-05-21 | 2022-01-25 | Amgen Inc | Formas en estado sólido |
WO2021003417A1 (fr) | 2019-07-03 | 2021-01-07 | Sumitomo Dainippon Pharma Oncology, Inc. | Inhibiteurs de tyrosine kinase non récepteur 1 (tnk1) et leurs utilisations |
CN114391012A (zh) | 2019-08-02 | 2022-04-22 | 美国安进公司 | 作为kif18a抑制剂的吡啶衍生物 |
US20220281843A1 (en) | 2019-08-02 | 2022-09-08 | Amgen Inc. | Kif18a inhibitors |
JP2022542319A (ja) | 2019-08-02 | 2022-09-30 | アムジエン・インコーポレーテツド | Kif18a阻害剤 |
CA3146693A1 (fr) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Inhibiteurs de kif18a |
TW202126636A (zh) | 2019-09-30 | 2021-07-16 | 美商阿吉歐斯製藥公司 | 作為menin抑制劑之六氫吡啶化合物 |
EP4048671A1 (fr) | 2019-10-24 | 2022-08-31 | Amgen Inc. | Dérivés de pyridopyrimidine utiles en tant qu'inhibiteurs de kras g12c et de kras g12d dans le traitement du cancer |
AU2020372881A1 (en) | 2019-10-28 | 2022-06-09 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS G12C mutant |
CN115551500A (zh) | 2019-10-31 | 2022-12-30 | 大鹏药品工业株式会社 | 4-氨基丁-2-烯酰胺衍生物及其盐 |
MX2022005360A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
WO2021091982A1 (fr) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
AU2020379731A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
CN116425742A (zh) | 2019-11-08 | 2023-07-14 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
WO2021097207A1 (fr) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Synthèse améliorée de composés inhibiteurs de kras g12c |
BR112022009390A2 (pt) | 2019-11-14 | 2022-08-09 | Amgen Inc | Síntese melhorada de composto inibidor de kras g12c |
WO2021108683A1 (fr) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Inhibiteurs de ras covalents et leurs utilisations |
WO2021106231A1 (fr) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | Composé ayant une activité inhibitrice contre la mutation kras g12d |
EP4087611A1 (fr) | 2020-01-07 | 2022-11-16 | Revolution Medicines, Inc. | Dosage d'inhibiteurs de shp2 et méthodes de traitement du cancer |
WO2021155006A1 (fr) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations |
EP4114852A1 (fr) | 2020-03-03 | 2023-01-11 | Sutro Biopharma, Inc. | Anticorps comprenant des étiquettes de glutamine spécifiques à un site, leurs procédés de préparation et d'utilisation |
TW202204333A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
TW202204334A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
WO2021215545A1 (fr) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Polythérapie anticancéreuse avec un inhibiteur de n-(1-acryloyl-azétidin-3-yl)-2-((1h-indazol-3-yl) amino) méthyl)-1 h-imidazole-5-carboxamide de kras-g12c |
EP4139299A1 (fr) | 2020-04-24 | 2023-03-01 | Taiho Pharmaceutical Co., Ltd. | Inhibiteurs de protéine kras g12d |
EP4168002A1 (fr) | 2020-06-18 | 2023-04-26 | Revolution Medicines, Inc. | Méthodes de retardement, de prévention et de traitement de la résistance acquise aux inhibiteurs de ras |
JP2023533982A (ja) | 2020-07-10 | 2023-08-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Gas41阻害剤及びその使用方法 |
TW202216151A (zh) | 2020-07-15 | 2022-05-01 | 日商大鵬藥品工業股份有限公司 | 含有使用於腫瘤之治療之嘧啶化合物之組合 |
KR20230081726A (ko) | 2020-09-03 | 2023-06-07 | 레볼루션 메디슨즈, 인크. | Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도 |
CN117683049A (zh) | 2020-09-15 | 2024-03-12 | 锐新医药公司 | 作为ras抑制剂以治疗癌症的吲哚衍生物 |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
JP2024501280A (ja) | 2020-12-22 | 2024-01-11 | キル・レガー・セラピューティクス・インコーポレーテッド | Sos1阻害剤およびその使用 |
KR20230170039A (ko) | 2021-04-13 | 2023-12-18 | 뉴베일런트, 아이엔씨. | Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클 |
KR20240004659A (ko) | 2021-04-30 | 2024-01-11 | 셀진 코포레이션 | 감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법 |
CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
US20230106174A1 (en) | 2021-05-05 | 2023-04-06 | Revolution Medicines, Inc. | Ras inhibitors |
KR20240017811A (ko) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
WO2022250170A1 (fr) | 2021-05-28 | 2022-12-01 | Taiho Pharmaceutical Co., Ltd. | Petites molécules inhibitrices de protéines mutées par kras |
WO2023056589A1 (fr) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Inhibiteurs de ménine et procédés d'utilisation pour le traitement du cancer |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023114954A1 (fr) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Composés pyrazolopyrazine utilisés comme inhibiteurs de la shp2 |
EP4227307A1 (fr) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2 |
WO2023172940A1 (fr) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Méthodes de traitement du cancer du poumon réfractaire immunitaire |
WO2023211812A1 (fr) | 2022-04-25 | 2023-11-02 | Nested Therapeutics, Inc. | Dérivés hétérocycliques en tant qu'inhibiteurs de protéine kinase activée par mitogène (mek) |
WO2023240263A1 (fr) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Inhibiteurs de ras macrocycliques |
US20240058465A1 (en) | 2022-06-30 | 2024-02-22 | Sutro Biopharma, Inc. | Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates |
WO2024010925A2 (fr) | 2022-07-08 | 2024-01-11 | Nested Therapeutics, Inc. | Inhibiteurs de protéine kinase activée par mitogène (mek) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03294252A (ja) * | 1990-04-13 | 1991-12-25 | Yamanouchi Pharmaceut Co Ltd | アミド化合物又はその塩 |
EP0634998B1 (fr) * | 1992-04-07 | 1997-03-19 | British Biotech Pharmaceuticals Limited | Inhibiteurs de la collagenase et de la cytokine a base d'acide hydroxamique |
GB9320660D0 (en) * | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
DE69624081T2 (de) * | 1995-12-20 | 2003-06-12 | Hoffmann La Roche | Matrix-metalloprotease Inhibitoren |
DE69728375T2 (de) * | 1996-01-02 | 2005-02-10 | Aventis Pharmaceuticals Inc. | Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen |
-
1998
- 1998-01-27 JP JP10534044A patent/JP2000507975A/ja active Pending
- 1998-01-27 BR BR9807824-0A patent/BR9807824A/pt not_active IP Right Cessation
- 1998-01-27 CA CA002279863A patent/CA2279863A1/fr not_active Abandoned
- 1998-01-27 EP EP98900334A patent/EP0966438A1/fr not_active Withdrawn
- 1998-01-27 WO PCT/IB1998/000101 patent/WO1998034915A1/fr not_active Application Discontinuation
- 1998-01-27 AU AU54935/98A patent/AU5493598A/en not_active Abandoned
- 1998-02-03 MA MA24954A patent/MA26472A1/fr unknown
- 1998-02-05 AP APAP/P/1998/001169A patent/AP9801169A0/en unknown
- 1998-02-05 TN TNTNSN98022A patent/TNSN98022A1/fr unknown
- 1998-02-06 ZA ZA9800970A patent/ZA98970B/xx unknown
- 1998-02-06 HR HR60/037,402A patent/HRP980062A2/hr not_active Application Discontinuation
- 1998-02-08 PA PA19988446001A patent/PA8446001A1/es unknown
- 1998-02-09 AR ARP980100550A patent/AR011116A1/es unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9834915A1 * |
Also Published As
Publication number | Publication date |
---|---|
HRP980062A2 (en) | 1998-12-31 |
AU5493598A (en) | 1998-08-26 |
AR011116A1 (es) | 2000-08-02 |
CA2279863A1 (fr) | 1998-08-13 |
PA8446001A1 (es) | 2000-05-24 |
BR9807824A (pt) | 2000-03-08 |
WO1998034915A1 (fr) | 1998-08-13 |
AP9801169A0 (en) | 1999-08-05 |
MA26472A1 (fr) | 2004-12-20 |
TNSN98022A1 (fr) | 2005-03-15 |
ZA98970B (en) | 1999-08-06 |
JP2000507975A (ja) | 2000-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998034915A1 (fr) | Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices | |
AU721748B2 (en) | Arylsulfonylamino hydroxamic acid derivatives | |
AU730248B2 (en) | Aryloxyarylsulfonylamino hydroxamic acid derivatives | |
AP733A (en) | Arylsulfonylamino hydroxamic acid derivatives. | |
EP0813520B1 (fr) | Derives de l'acide arylsulfonylamino hydroxamique | |
EP0950059B1 (fr) | Derives de sulfone cyclique | |
AU3104297A (en) | Phosphinate based inhibitors of matrix metalloproteases | |
EP0895988B1 (fr) | Dérivés de l'acide arylsulfonamino-hydroxamique | |
US20020006920A1 (en) | Arylsulfonylamino hydroxamic acid derivatives | |
US6147074A (en) | Arylsulfonylamino hydroxamic acid derivatives | |
US6107337A (en) | Arylsulfonylamino hydroxamic acid derivatives | |
MXPA99007315A (en) | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases | |
EP1415984A1 (fr) | Dérivés de l'acide aryloxyarylsulfonylaminohydroxamique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990805 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20020115 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20020528 |